Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of HRS-5965 capsules, indicating progress in the drug approval process for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in adult patients [1]. Group 1 - The drug name is Fumaric Acid Likanopam Capsules [1] - The dosage form is capsule [1] - The acceptance number for the application is CXHS2600014 [1] - The application is currently in the marketing phase [1] - The applicant is Chengdu Shengdi Pharmaceutical Co., Ltd. [1] - The intended indication is for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1]